{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-052642","form_type":"8-K","ticker":"AZTA","cik":"0000933974","company_name":"Azenta, Inc.","filed_at":"2026-08-04T20:32:44+00:00","discovered_at":"2026-08-04T20:34:16.294291+00:00","generated_at":"2026-08-04T20:34:39.172192+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Azenta Reports Q3 Fiscal 2026 Revenue of $161M, Up 12% YoY","bullets":["Revenue from continuing operations was $161M, up 12% year over year; organic growth was 9%.","Sample Management Solutions revenue rose 14% to $88M; Multiomics revenue rose 10% to $73M.","Diluted EPS from continuing operations was ($0.03); total diluted EPS was $0.05, compared to ($1.05) a year ago.","Adjusted EBITDA from continuing operations was $18.5M, with margin of 11.4%.","Sale of B Medical Systems closed on July 1, 2026; results reported as discontinued operations."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-052642","json":"https://secwatch.observer/filing/0001628280-26-052642.json","markdown":"https://secwatch.observer/filing/0001628280-26-052642.md","text":"https://secwatch.observer/filing/0001628280-26-052642.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/933974/000162828026052642/0001628280-26-052642-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/933974/000162828026052642/azta-20260804.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-04T20:34:39.172192+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}